Evidence map›Paper›PMID 34420893›Full record

ArticleClinical lymphoma, myeloma & leukemia2021

Management and Outcome of Coronavirus Disease 2019 (COVID-19) in Pediatric Cancer Patients: A Single Centre Experience from a Developing Country.

Mahmoud Hammad, Lobna Shalaby, Iman Sidhom, Nancy Sherief, Ibrahim Abdo, Sonia Soliman, Youssef Madeny, Reem Hassan, Shaimaa Elmeniawy, Nagwa Khamis and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical lymphoma, myeloma & leukemia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.Journal of the Pediatric Infectious Diseases Society · 2024
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Clinical Outcomes of Pediatric Cancer Patients with COVID-19: A Cross-Sectional Study.International journal of hematology-oncology and stem cell research · 2024
    Article
  9. Review
  10. Risk Factors for Pediatric Critical COVID-19: A Systematic Review and Meta-Analysis.medRxiv : the preprint server for health sciences · 2024
    Article
  11. Article
  12. Review
  13. Ferritin in pediatric critical illness: a scoping review.Clinical and experimental pediatrics · 2023
    Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Mahmoud HammadPediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt. Electronic address: Mahmoud.hammad@nci.cu.edu.eg.
Lobna ShalabyPediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Iman SidhomPediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Nancy SheriefClinical Research Department Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Ibrahim AbdoClinical Pharmacy Department Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Sonia SolimanClinical Pathology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Youssef MadenyPediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Reem HassanClinical and Chemical Pathology Department Faculty of Medicine, Cairo University and Clinical Pathology Department Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Shaimaa ElmeniawyContinuous Performance Improvement Department Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Nagwa KhamisClinical Pathology Department Ain Shams University and Infection Control Department Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Iman ZakiRadio-diagnosis Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Tarek MansourVirology and Immunology Department, National Cancer Institute, Cairo University and Clinical Pathology Department Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Mohamed Gamal El-AnsaryIntensive Care Unit Department, Kasr Al-Ainy Cairo University, Cairo, Egypt.
Ahmed Al-HalfawyPulmonology Medicine Department, Kasr Al-Ainy Cairo University, Cairo, Egypt.
Sherif AbouelnagaPediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.
Alaa ElhaddadPediatric Oncology Department National Cancer Institute, Cairo University and Children's Cancer Hospital Egypt (CCHE-57357). Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSufficient data pertaining to the impact of the Coronavirus disease 2019 (COVID-19) on pediatric cancer patients is still lacking. The aim of this prospective study was to describe clinical management and outcomes of COVID-19 in pediatric oncology patients. PATIENTS AND

methodsConducted between May 1, 2020 and November 30, 2020, this study included 76 pediatric oncology patients with confirmed COVID-19. Remdesivir (RDV) was the antiviral therapy used.

resultsThe median age of patients was 9 years. Sixty patients were on first line treatment. Hematological malignancies constituted 86.8% of patients. Severe to critical infections were 35.4% of patients. The commonest symptom was fever (93.4%). Chemotherapy was delayed in 59.2% of patients and doses were modified in 30.2%. The 60-day overall survival (OS) stood at 86.8%, with mortalities occurring only among critical patients. Of sixteen acute leukemia patients in the first induction therapy, 13 survived and 10 achieved complete remission. A negative RT-PCR within 2 weeks and improvement of radiological findings were statistically related to disease severity (P = .008 and .002, respectively). Better OS was associated with regression of radiological findings after 30 days from infection (P = .002). Forty-five patients received RDV, 42.1% had severe and critical forms of infection compared to 25.7% in the No-RDV group and yet OS was comparable in both groups.

conclusionMost pediatric cancer patients with COVID-19 should have good clinical outcomes except for patients with critical infections. Cancer patients can tolerate chemotherapy including induction phase, alongside COVID-19 treatment. In severe and critical COVID-19, RDV might have a potential benefit.

Indexed as

Adenosine MonophosphateAdolescentAlanineAntiviral AgentsChildChild, PreschoolCOVID-19Developing CountriesFemaleHumansInfantMaleNeoplasmsProspective StudiesSARS-CoV-2Severity of Illness IndexAdenosine MonophosphateAlanineAntiviral AgentsremdesivirCOVID-19immunocompromised patientspediatric cancerremdesivirSARS-CoV-2

Identifiers

PMID34420893
PMCPMC8312090

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.